Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	NOVAKOVA-JIRESOVA Alena KOPECKOVA Katerina BOUBLIKOVA Ludmila CHLOUPKOVÁ Renata MELICHAR Bohuslav PETRUZELKA Lubos FINEK Jindrich FIALA Ondrej GRELL Peter BATKO Stanislav LINKE Zdenek KISS Igor PRAUSOVA Jana BÜCHLER Tomáš
Year of publication	2020
Type	Article in Periodical
Magazine / Source	CANCER MANAGEMENT AND RESEARCH
MU Faculty or unit	Faculty of Medicine
Citation
web	https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1597040957_5f30e93d90283/cmar-255332-regorafenib-for-metastatic-colorectal-cancer-an-analysis-of.pdf
Doi	http://dx.doi.org/10.2147/CMAR.S255332
Keywords	colorectal cancer; regorafenib; registry; survival; outcome analysis
Description	Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.